PE20221911A1 - Uso de agentes para el tratamiento de condiciones respiratorias - Google Patents
Uso de agentes para el tratamiento de condiciones respiratoriasInfo
- Publication number
- PE20221911A1 PE20221911A1 PE2022002100A PE2022002100A PE20221911A1 PE 20221911 A1 PE20221911 A1 PE 20221911A1 PE 2022002100 A PE2022002100 A PE 2022002100A PE 2022002100 A PE2022002100 A PE 2022002100A PE 20221911 A1 PE20221911 A1 PE 20221911A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- covid
- gaba
- pam
- agents
- Prior art date
Links
- 230000000241 respiratory effect Effects 0.000 title 1
- 208000025721 COVID-19 Diseases 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 238000005399 mechanical ventilation Methods 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Refiere a metodos para tratar un sintoma de una enfermedad o condicion respiratoria asociada con la COVID-19 en sujetos menores o mayores de 70 anos. Dicho metodo comprende administrar una cantidad terapeuticamente efectiva de una GABAA PAM, o una sal farmaceuticamente aceptable o forma cristalina de la misma, la cual se selecciona de los Compuestos 1 y 2 mencionados en la presente. Asimismo, la GABAA PAM se administra antes, despues o simultaneamente junto a un relajante de musculo bronquial/via aerea, un antiviral, oxigeno, un anticuerpo y un antibacteriano a una velocidad de 90-160 ?g/kg por hora en sujetos con tratamiento fibrotico y/o ventilacion mecanica, para aumentar la saturacion de oxigeno en la sangre y mejorar uno o mas sintomas de COVID-19 tales como la neumonia y bronquitis.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062994803P | 2020-03-25 | 2020-03-25 | |
US202062994805P | 2020-03-25 | 2020-03-25 | |
US202063000415P | 2020-03-26 | 2020-03-26 | |
US202063000418P | 2020-03-26 | 2020-03-26 | |
US202063006672P | 2020-04-07 | 2020-04-07 | |
US202063006671P | 2020-04-07 | 2020-04-07 | |
US202063063803P | 2020-08-10 | 2020-08-10 | |
US202063063780P | 2020-08-10 | 2020-08-10 | |
PCT/US2021/024010 WO2021195297A1 (en) | 2020-03-25 | 2021-03-24 | Use of agents for treatment of respiratory conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20221911A1 true PE20221911A1 (es) | 2022-12-23 |
Family
ID=75478347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022002100A PE20221911A1 (es) | 2020-03-25 | 2021-03-24 | Uso de agentes para el tratamiento de condiciones respiratorias |
Country Status (15)
Country | Link |
---|---|
US (2) | US20230346801A1 (es) |
EP (1) | EP4125921A1 (es) |
JP (1) | JP2023519241A (es) |
KR (1) | KR20220157426A (es) |
CN (1) | CN115551514A (es) |
AU (1) | AU2021241622A1 (es) |
BR (1) | BR112022019085A2 (es) |
CA (1) | CA3176854A1 (es) |
CL (1) | CL2022002592A1 (es) |
CO (1) | CO2022013777A2 (es) |
IL (1) | IL296645A (es) |
MX (1) | MX2022011804A (es) |
PE (1) | PE20221911A1 (es) |
TW (2) | TW202202146A (es) |
WO (2) | WO2021195301A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014018110B1 (pt) | 2012-01-23 | 2022-06-07 | Sage Therapeutics, Inc | Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
PT3224269T (pt) | 2014-11-27 | 2020-06-01 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios do snc |
CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
EP4217002A1 (en) * | 2020-09-25 | 2023-08-02 | The Regents of the University of California | Compositions and methods for ameliorating medical conditions |
KR20230124916A (ko) * | 2020-11-25 | 2023-08-28 | 세이지 테라퓨틱스, 인크. | Cns 장애를 치료하기 위한 조성물 및 방법 |
TW202341997A (zh) * | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
WO2024020953A1 (zh) * | 2022-07-28 | 2024-02-01 | 湖南科益新生物医药有限公司 | 治疗中枢神经***疾病的甾体化合物及其制备方法、用途和药物组合物 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ20013867A3 (cs) | 1999-04-29 | 2002-07-17 | Purdue Pharma Ltd. | 3alfa-hydroxy-3beta-methoxymethyl-21-heterocyklem substituované steroidy s anestetickým účinkem |
CA2852057C (en) | 2011-10-14 | 2022-06-07 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
BR112014018110B1 (pt) | 2012-01-23 | 2022-06-07 | Sage Therapeutics, Inc | Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina |
WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
KR102305359B1 (ko) | 2012-08-21 | 2021-09-24 | 세이지 테라퓨틱스, 인크. | 간질 또는 간질지속 상태를 치료하는 방법 |
CA2892811A1 (en) | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression |
BR112015014397B1 (pt) | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
LT2986624T (lt) | 2013-04-17 | 2020-07-10 | Sage Therapeutics, Inc. | Neuroaktyvūs 9-nor steroidai, skirti gydymo metodams |
US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
AU2014290400B2 (en) | 2013-07-19 | 2019-12-05 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
PT3035940T (pt) | 2013-08-23 | 2019-01-28 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US10172870B2 (en) * | 2014-09-02 | 2019-01-08 | The Texas A&M University System | Method of treating organophosphate intoxication by administration of neurosteroids |
JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
EP3753927B1 (en) | 2014-10-16 | 2023-07-19 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
KR102612943B1 (ko) | 2014-10-16 | 2023-12-13 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 조성물 및 방법 |
PT3224269T (pt) | 2014-11-27 | 2020-06-01 | Sage Therapeutics Inc | Composições e métodos para tratamento de distúrbios do snc |
SI3250210T1 (sl) | 2015-01-26 | 2021-07-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
US10329320B2 (en) | 2015-02-20 | 2019-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
CN109414444A (zh) | 2016-03-08 | 2019-03-01 | 萨奇治疗股份有限公司 | 神经活性类固醇、其组合物及用途 |
EP4302764A2 (en) | 2016-07-11 | 2024-01-10 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
CN115974954A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
TW202342058A (zh) | 2017-09-07 | 2023-11-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
US20210101928A1 (en) | 2017-12-22 | 2021-04-08 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
WO2019140272A1 (en) | 2018-01-12 | 2019-07-18 | Sage Therapeutics, Inc. | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
US20210139530A1 (en) | 2018-02-11 | 2021-05-13 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
US20210205329A1 (en) * | 2018-05-21 | 2021-07-08 | The University Of North Carolina At Chapel Hill | Methods of inhibiting proinflammatory neuroimmune signaling and treating inflammatory disorders |
US20210338692A1 (en) | 2018-06-12 | 2021-11-04 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
US20210177805A1 (en) * | 2018-08-22 | 2021-06-17 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma |
US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
WO2020185710A1 (en) * | 2019-03-08 | 2020-09-17 | Alairion, Inc. | Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor |
-
2021
- 2021-03-24 IL IL296645A patent/IL296645A/en unknown
- 2021-03-24 KR KR1020227035963A patent/KR20220157426A/ko active Search and Examination
- 2021-03-24 US US17/913,936 patent/US20230346801A1/en active Pending
- 2021-03-24 CA CA3176854A patent/CA3176854A1/en active Pending
- 2021-03-24 MX MX2022011804A patent/MX2022011804A/es unknown
- 2021-03-24 PE PE2022002100A patent/PE20221911A1/es unknown
- 2021-03-24 WO PCT/US2021/024014 patent/WO2021195301A1/en active Application Filing
- 2021-03-24 AU AU2021241622A patent/AU2021241622A1/en active Pending
- 2021-03-24 EP EP21719408.3A patent/EP4125921A1/en active Pending
- 2021-03-24 CN CN202180034342.3A patent/CN115551514A/zh active Pending
- 2021-03-24 US US17/913,916 patent/US20230414636A1/en active Pending
- 2021-03-24 JP JP2022557755A patent/JP2023519241A/ja active Pending
- 2021-03-24 WO PCT/US2021/024010 patent/WO2021195297A1/en unknown
- 2021-03-24 BR BR112022019085A patent/BR112022019085A2/pt unknown
- 2021-03-25 TW TW110110914A patent/TW202202146A/zh unknown
- 2021-03-25 TW TW110110915A patent/TW202143977A/zh unknown
-
2022
- 2022-09-23 CL CL2022002592A patent/CL2022002592A1/es unknown
- 2022-09-26 CO CONC2022/0013777A patent/CO2022013777A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN115551514A (zh) | 2022-12-30 |
TW202202146A (zh) | 2022-01-16 |
IL296645A (en) | 2022-11-01 |
EP4125921A1 (en) | 2023-02-08 |
CL2022002592A1 (es) | 2023-04-21 |
MX2022011804A (es) | 2023-03-09 |
CA3176854A1 (en) | 2021-09-30 |
KR20220157426A (ko) | 2022-11-29 |
WO2021195301A1 (en) | 2021-09-30 |
AU2021241622A1 (en) | 2022-10-20 |
CO2022013777A2 (es) | 2022-10-11 |
WO2021195297A1 (en) | 2021-09-30 |
US20230414636A1 (en) | 2023-12-28 |
US20230346801A1 (en) | 2023-11-02 |
BR112022019085A2 (pt) | 2023-01-31 |
TW202143977A (zh) | 2021-12-01 |
JP2023519241A (ja) | 2023-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20221911A1 (es) | Uso de agentes para el tratamiento de condiciones respiratorias | |
Müller | The role of anti-inflammatory treatment in psychiatric disorders | |
Zheng et al. | NF-κB/P65 signaling pathway: a potential therapeutic target in postoperative cognitive dysfunction after sevoflurane anesthesia | |
AR078588A1 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
UY32562A (es) | Pirimidinas sustituidas por imidazol 724 | |
RU2007133444A (ru) | Способ лечения, профилактики или уменьшения системного воспаления у детей на искусственном вскармливании | |
Saavedra et al. | Long-term activation of hippocampal glial cells and altered emotional behavior in male and female adult rats after different neonatal stressors | |
Kobayashi et al. | Candida esophagitis and laryngitis in chronic mucocutaneous candidiasis | |
Bansod et al. | Abamectin: an uncommon but potentially fatal cause of pesticide poisoning | |
CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
RU2014138880A (ru) | Введение эриторана или его фармацевтически приемлемых солей для лечения ортомиксовирусных инфекций | |
Schwartz et al. | The Management of Massive Tuberculous Pneumonia, A Therapeutic Review of Seventy-Five Cases | |
ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
Lin et al. | Clinical study on functional dyspepsia by auricular point sticking therapy | |
ES2864853T3 (es) | Pacritinib para su uso en el tratamiento de rechazo de trasplante | |
RU2294758C2 (ru) | Способ лечения хронического аденоидита у детей | |
UA9746U (en) | Method for treating affective disorders with copulative dysfunction | |
Zasieda | MODERN METHODS OF NON-INFLAMMATORY CHRONIC PELVIC PAIN SYNDROME TREATMENT | |
Pol | Antineoplastics/defibrotide | |
Christensen et al. | Hyperbaric oxygen therapy in mice injected with tetanus toxin | |
Zhang et al. | Abstract P-166: FUNCTIONAL INFLUENCES OF AUTOPHAGY ON CARDIOMYOCYTE EXCITATION-CONTRACTION IN SEPTIC SHOCK | |
UA51728U (uk) | Спосіб лікування ентеровірусної інфекції | |
Cascella | The controversial experiments on the intravenous administration of drugs (and air!) during the cholera epidemic of 1867 in Italy | |
JELLIFFE | Postencephalitic respiratory syndromes: phenomenology and pathologic considerations |